☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Vasomotor Symptoms
Bayer Initiates P-III OASIS Program of Elinzanetant for the Treatment of Vasomotor Symptoms During Menopause
September 1, 2021
Bayer to Acquire KaNDy Therapeutics for Augmenting its Women's Healthcare Portfolio
August 11, 2020
Astellas Initiates P-III BRIGHT SKY Clinical Program for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms
August 6, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.